|
1)
Thrombotic thrombocytopenic purpura secondary to an occult
adenocarcinoma.
Pirrotta MT, Bucalossi A, Forconi F, Bocchia M, Mazzotta S,
Sammassimo S, Gozzetti A, Lauria F.
Oncologist. 2005 Apr;10(4):299-300.
2)
Effect of a p210 multipeptide vaccine associated with imatinib or
interferon in patients with chronic myeloid leukaemia and persistent
residual disease: a multicentre observational trial.
Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A,
Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F.
Lancet.
2005 Feb 19-25;365(9460):657-62.
3)
Comprehensive characterization of IGHV3-21-expressing B-cell chronic
lymphocytic leukemia: an Italian multicenter study.
Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A,
Forconi F, Maffei R, Ghia EM, Laurenti L, Bulian P, Del Principe MI,
Palermo G, Thorsélius M, Degan M, Campanini R, Guarini A, Del Poeta
G, Rosenquist R, Efremov DG, Marasca R, Foà R, Gaidano G, Gattei V.
Blood.
2007 Apr 1;109(7):2989-98.
|